V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310005592 | 310002605 | 1.9 | -1 | Palliative (P) | 2017-09-07 | 2017-10-03 | BEP 5 Day | N | Y | 310024857 | CARBOPLATIN + VINORELBINE |
| 310005593 | 310002606 | 0 | 68 | Palliative (P) | 2017-09-21 | 2017-10-03 | SelPac Trial | null | N | 310024859 | PAZOPANIB |
| 310005594 | 310002606 | 1.55 | 72.4 | Curative (C) | 2018-02-02 | 2018-02-02 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | N | N | 310024859 | BEVACIZUMAB |
| 310005595 | 310002607 | 1.53 | 48.6 | Palliative (P) | 2016-01-10 | 2016-01-14 | Sunitinib | 02 | null | 310025018 | ESHAP |
| 310005596 | 310002608 | null | 64.5 | Adjuvant (A) | 2018-08-03 | 2018-08-04 | FEC 100 | N | null | 310025026 | ECARBOX |
| 310005597 | 310002609 | 1.68 | null | Curative (C) | 2018-11-04 | 2018-11-25 | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + VINCRISTINE | null | N | 310025028 | CARBOPLATIN + PEMETREXED |
| 310005598 | 310002610 | 1.65 | null | Curative (C) | 2014-07-22 | 2014-08-01 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 2 | N | 310025101 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 310005599 | 310002611 | 1.81 | 52.6 | Curative (C) | 2018-04-26 | 2018-05-03 | VISMODEGIB | N | N | 310025173 | NIVOLUMAB |
| 310005600 | 310002611 | 1.62 | 70.8 | Palliative (P) | 2013-07-15 | 2013-07-26 | MITOMYCIN | N | N | 310025173 | DOXORUBICIN + IFOSFAMIDE |
| 310005601 | 310002612 | 1.75 | 50.5 | Palliative (P) | 2016-12-06 | 2016-12-11 | DABRAFENIB | N | Y | 310025195 | CETUXIMAB + RT |
| 310005602 | 310002613 | 1.71 | 76.7 | Curative (C) | 2015-04-11 | 2015-04-12 | Pazopanib | N | N | 310025206 | CAPECITABINE + CISPLATIN + RT |
| 310005603 | 310002614 | null | 96 | Curative (C) | 2018-01-03 | 2018-01-17 | FEC | N | N | 310025220 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 310005604 | 310002615 | 1.82 | 71.4 | Curative (C) | 2017-12-22 | 2018-01-09 | Pazopanib | N | N | 310025243 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310005605 | 310002616 | 1.65 | 56 | Neo-adjuvant (N) | 2016-02-27 | 2016-03-05 | ICON8B TRIAL | N | N | 310025256 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310005606 | 310002617 | 1.75 | 67.1 | Palliative (P) | 2017-09-15 | 2017-09-16 | ALL UKALL2011 Ind B Sht Dex (PAsp) | 02 | N | 310025273 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 310005607 | 310002618 | 1.75 | 96 | Curative (C) | 2018-09-15 | 2018-09-15 | Cyclophosphamide oral | N | N | 310025293 | AML16 TRIAL |
| 310005608 | 310002619 | 1.68 | 66 | Unknown (U) | 2017-02-11 | 2017-02-27 | FEC + DOCETAXEL | N | 2 | 310025295 | CARBOPLATIN + LIPOSOMAL DOX |
| 310005609 | 310002620 | 1.79 | 33.6 | Palliative (P) | 2018-11-10 | 2019-01-08 | CMV | N | N | 310025314 | DA |
| 310005610 | 310002621 | 1.5 | 55.6 | Palliative (P) | 2014-03-20 | 2014-03-27 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 310025368 | FEC |
| 310005611 | 310002622 | 1.56 | 59 | Disease modification (D) | 2018-02-23 | 2018-02-25 | CVP R + GEMCITABINE | 01 | N | 310025400 | CAPECITABINE + MITOMYCIN |
| 310005612 | 310002623 | 0 | 56 | Palliative (P) | 2015-05-09 | 2015-05-09 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 310025418 | DABRAFENIB + TRAMETINIB |
| 310005613 | 310002624 | 1.83 | 59 | Curative (C) | 2013-09-09 | 2013-09-09 | POUT TRIAL | 02 | N | 310025461 | CARBOPLATIN + RT |
| 310005614 | 310002625 | 1.74 | null | Palliative (P) | 2017-05-28 | 2017-06-05 | LANREOTIDE | N | N | 310025467 | BEP |
| 310005615 | 310002625 | null | null | Palliative (P) | 2017-06-03 | 2018-01-10 | ICON8B TRIAL | 2 | N | 310025467 | METHOTREXATE HIGH DOSE |
| 310005616 | 310002626 | null | 22.3 | Curative (C) | 2018-03-28 | 2018-04-08 | R GCVP | 02 | N | 310025486 | CETUXIMAB + RT |
| 310005617 | 310002626 | null | 64 | Curative (C) | 2017-02-03 | 2017-02-03 | STS Rhabdomyosarcoma RMS 2005 IVA | N | null | 310025486 | GEMCITABINE + OXALIPLATIN |
| 310005618 | 310009298 | null | null | Disease modification (D) | 2013-07-19 | 2013-07-23 | ALL UKALL2011 IndB Std Dex (PegAsp) | 02 | null | 310025559 | POUT TRIAL |
| 310005619 | 310010463 | 1.73 | 84.5 | Disease modification (D) | 2018-10-20 | 2018-10-22 | Cetuximab + Radiotherapy Maint | 02 | N | 310025565 | CARBO + FLUOROURACIL |
| 310005620 | 310002627 | 1.82 | 111 | Not known (9) | 2015-01-26 | 2015-02-15 | GDP | 02 | N | 310025610 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 310005621 | 310002628 | 1.65 | 75.4 | Palliative (P) | 2015-10-29 | 2015-11-18 | Gemcitabine + Capecitabine | 02 | N | 310025625 | CYCLOPHOSPHAMIDE + LIPOSOMAL DOX |
| 310005622 | 310002629 | 1.76 | 58 | Curative (C) | 2018-06-09 | 2018-06-17 | OCTREOTIDE | N | N | 310025640 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 310005623 | 310002629 | 1.7 | 98 | null | 2016-07-24 | 2016-08-03 | Cisplatin + Pemetrexed | N | N | 310025640 | IVE |
| 310005624 | 310002629 | 1.84 | 70.3 | Palliative (P) | 2017-10-05 | 2017-10-11 | Abiraterone | Y | N | 310025640 | PAZOPANIB |
| 310005625 | 310002630 | 1.68 | 56.7 | Curative (C) | 2016-07-09 | 2016-08-27 | Cyclophosphamide + Vincristine | 2 | N | 310025657 | BEVACIZUMAB |
| 310005626 | 310002631 | null | 96 | null | 2016-11-19 | 2016-11-19 | STS Rhabdomyosarcoma RMS 2005 IVADo | Y | N | 310025663 | IVA |
| 310005627 | 310002631 | 1.57 | 56.7 | Disease modification (D) | 2016-03-15 | 2016-03-15 | POMALIDOMIDE | N | N | 310025663 | CVP R |
| 310005628 | 310002632 | 1.52 | 78.3 | Palliative (P) | 2017-02-26 | 2017-03-10 | Sunitinib | N | N | 310025697 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 310005629 | 310007086 | 1.7 | 84.2 | Curative (C) | 2015-03-18 | 2015-04-07 | CYCLOPHOSPHAMIDE + LIPOSOMAL DOX | N | N | 310025707 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310005630 | 310007086 | 1.77 | null | Palliative (P) | 2014-07-25 | 2014-07-25 | GEMCITABINE + VINORELBINE | N | N | 310025707 | R-EPOCH |
| 310005631 | 310010464 | 1.63 | 59.2 | Palliative (P) | 2014-06-10 | 2014-06-24 | CETUXIMAB + RT | N | N | 310025747 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 310005632 | 310010464 | 1.63 | null | null | 2016-11-13 | 2016-11-17 | Bevacizumab 7.5mg/kg | Y | null | 310025747 | CHLORAMBUCIL |
| 310005633 | 310002633 | 1.71 | 70 | Curative (C) | 2014-12-10 | 2014-12-10 | CARBOPLATIN + VINORELBINE | N | N | 310000159 | CETUXIMAB + RT |
| 310005634 | 310002634 | 1.7 | 108 | Neo-adjuvant (N) | 2016-09-30 | 2016-10-13 | R GCVP | N | N | 310000178 | CAPECITABINE + CARBOPLATIN |
| 310005635 | 310002634 | 1.72 | null | Curative (C) | 2017-09-07 | 2018-08-22 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 02 | N | 310000178 | CARBOPLATIN + RT |
| 310005636 | 310002635 | 1.75 | null | Palliative (P) | 2016-06-29 | 2016-06-30 | IVE | 02 | null | 310000213 | CHLORAMBUCIL |
| 310005637 | 310002636 | 1.81 | 92 | Disease modification (D) | 2017-04-19 | 2016-12-28 | Doxorubicin + Ifosfamide | N | N | 310000470 | CARBOPLATIN + VINORELBINE |
| 310005638 | 310002637 | 1.65 | 88 | Curative (C) | 2016-05-10 | 2016-05-10 | EC | 02 | N | 310001814 | CISPLATIN + PEMETREXED |
| 310005639 | 310007088 | 1.68 | null | Neo-adjuvant (N) | 2018-02-02 | 2018-02-23 | Cisplatin + Etoposide + RT | 02 | N | 310001830 | ETOPOSIDE |
| 310005640 | 310009301 | 1.73 | 67.2 | Palliative (P) | 2017-12-13 | 2017-12-13 | Trastuzumab Subcutaneous | N | N | 310001900 | CARBOPLATIN + LIPOSOMAL DOX |
| 310005641 | 310002638 | null | 9.3 | Curative (C) | 2013-06-11 | 2013-06-13 | FEC + DOCETAXEL | N | N | 310002013 | ICON8B TRIAL |